Patient characteristics
| . | SCA CTT cohort (n = 21) . | SCA non-CTT cohort (n = 21) . | Control cohort (n = 13) . | P . |
|---|---|---|---|---|
| Mean age (range) at scan, y | 13.1 (6-21) | 11.5 (6-21) | 11.2 (6-17) | .55 |
| Male sex, no. (%) | 9 (43) | 9 (43) | 9 (64) | .25 |
| Hb, no. (%) | ||||
| SS | 20 (95) | 19 (90) | NA | |
| S-β0 thalassemia | 1 (5) | 2 (10) | NA | |
| Vasculopathy, no. (%) | 7 (33) | 0 | 0 | |
| Indication for CTT, no. (%) | NA | NA | ||
| Overt stroke/TIA | 10 (48) | |||
| Silent stroke | 5 (24) | |||
| Abnormal TCD | 6 (29) | |||
| Type of CTT, no. (%) | NA | NA | ||
| Manual exchange transfusion | 17 (81) | |||
| Erythrocytapheresis | 4 (19) | |||
| Median Hb (25th-75th IQR), g/dL* | 8.5 (7.7-9.5) | 13.3 (12.7-14.2) | <.001† | |
| Pretransfusion | 9.1 (8.8-9.6) | |||
| Posttransfusion | 10.3 (10.1-11.0) | |||
| P | <.001 | |||
| Median Hb S (25th-75th IQR), % | 74.4 (67.8-81.3) | NA | <.001† | |
| Pretransfusion | 39.7 (31.7-48.1) | |||
| Posttransfusion | 24.3 (17.1-33.1) | |||
| P | <.001 | |||
| Median SpO2(25th-75th IQR), % | 97 (94-99) | 99 (98-100) | .03† | |
| Pretransfusion | 98 (97-98) | |||
| Posttransfusion | 98 (96-99) | |||
| P | .307 | |||
| Median dyshemoglobins (25th-75th IQR), % | 4.2 (4.1-4.4) | 1.8 (1.5-1.8) | <.001† | |
| Pretransfusion | 4.0 (3.7-4.4) | |||
| Posttransfusion | 3.6 (3.3-4.0) | |||
| P | .02 | |||
| Median calculated CaO2(25th-75th IQR), mL/dL | 10.6 (9.5-12.2) | 17.7 (17.0-18.6) | <.001† | |
| Pretransfusion | 11.9 (11.1-12.4) | |||
| Posttransfusion | 13.3 (12.4-14.0) | |||
| P | <.001 |
| . | SCA CTT cohort (n = 21) . | SCA non-CTT cohort (n = 21) . | Control cohort (n = 13) . | P . |
|---|---|---|---|---|
| Mean age (range) at scan, y | 13.1 (6-21) | 11.5 (6-21) | 11.2 (6-17) | .55 |
| Male sex, no. (%) | 9 (43) | 9 (43) | 9 (64) | .25 |
| Hb, no. (%) | ||||
| SS | 20 (95) | 19 (90) | NA | |
| S-β0 thalassemia | 1 (5) | 2 (10) | NA | |
| Vasculopathy, no. (%) | 7 (33) | 0 | 0 | |
| Indication for CTT, no. (%) | NA | NA | ||
| Overt stroke/TIA | 10 (48) | |||
| Silent stroke | 5 (24) | |||
| Abnormal TCD | 6 (29) | |||
| Type of CTT, no. (%) | NA | NA | ||
| Manual exchange transfusion | 17 (81) | |||
| Erythrocytapheresis | 4 (19) | |||
| Median Hb (25th-75th IQR), g/dL* | 8.5 (7.7-9.5) | 13.3 (12.7-14.2) | <.001† | |
| Pretransfusion | 9.1 (8.8-9.6) | |||
| Posttransfusion | 10.3 (10.1-11.0) | |||
| P | <.001 | |||
| Median Hb S (25th-75th IQR), % | 74.4 (67.8-81.3) | NA | <.001† | |
| Pretransfusion | 39.7 (31.7-48.1) | |||
| Posttransfusion | 24.3 (17.1-33.1) | |||
| P | <.001 | |||
| Median SpO2(25th-75th IQR), % | 97 (94-99) | 99 (98-100) | .03† | |
| Pretransfusion | 98 (97-98) | |||
| Posttransfusion | 98 (96-99) | |||
| P | .307 | |||
| Median dyshemoglobins (25th-75th IQR), % | 4.2 (4.1-4.4) | 1.8 (1.5-1.8) | <.001† | |
| Pretransfusion | 4.0 (3.7-4.4) | |||
| Posttransfusion | 3.6 (3.3-4.0) | |||
| P | .02 | |||
| Median calculated CaO2(25th-75th IQR), mL/dL | 10.6 (9.5-12.2) | 17.7 (17.0-18.6) | <.001† | |
| Pretransfusion | 11.9 (11.1-12.4) | |||
| Posttransfusion | 13.3 (12.4-14.0) | |||
| P | <.001 |